top of page
ARVO 2026: DURABLE RETINA THERAPEUTICS SHOWCASE
Moderators: Robert L. Avery, MD and Lejla Vajzovic, MD
Panel: Michael Goldstein, MD and Garrett Hamontree
Room: 403
Start | Company | Presenter |
|---|---|---|
1:30 PM | Introduction | Robert L. Avery, MD |
1:31 PM | AAVantgarde | Natalia Misciattelli, PhD, CEO |
1:36 PM | Adverum Biotechnologies, Inc., a wholly owned subsidiary of Eli Lilly and Company | Star Seyedkazemi, PharmD, Chief Development Officer |
1:41 PM | Discussion | |
1:44 PM | Coave Therapeutics | Rodolphe Clerval, CEO |
1:49 PM | Restore Vision, Inc | Elizabeth K. Messersmith, PhD, Consultant, Clinical Dev and R&D Strategy |
1:57 PM | Discussion | |
2:00 PM | Luxa Biotechnology | Keith Dionne, PhD, CEO |
2:05 PM | Astellas Pharma | Ha Tran, MD, MS, Medical Head, BioPharma and Ophthalmology Development |
2:10 PM | Discussion | |
2:13 PM | EyePoint, Inc | Ramiro Ribeiro MD, PhD, Chief Medical Officer |
2:18 PM | Ocular Therapeutix, Inc | Peter Kaiser MD, Chief Development Officer |
2:23 PM | Asvattha Therapeutics, Inc | Susan Schneider, MD, Acting Chief Medical Officer |
2:28 PM | Discussion | |
2:32 PM | Neurotech Pharmaceuticals, Inc | Rich Small, CEO |
2:37 PM | Re-Vana Therapeutics | Hans Christinger, Chief Business Officer |
2:42 PM | Discussion | |
2:45 PM | Optigo Biotherapeutics | Ali Ardakani, CEO |
2:50 PM | Valitor | Wesley M. Jackson, PhD, VP, Business Development |
2:55 PM | Discussion | |
2:58 PM | Conclusion | LejlaVajzovic, MD |
3:00 PM | End of Session |
Anchor 1
bottom of page